News/ News/ Oncology Boehringer buys immunotherapy biotech AMAL Therapeutics Richard Staines AMAL Therapeutics, BI, vaccines in oncology 0 Comment Germany’s Boehringer Ingelheim has bought the Swiss biotech AMAL Therapeutics, a privately-held Swiss biotech focused on immunotherapy and Share X Boehringer buys immunotherapy biotech AMAL Therapeutics https://pharmaphorum.com/news/boehringer-buys-immunotherapy-biotech-amal-therapeutics/
